Management of hypertension in patients with chronic kidney disease in Asia

On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG)

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Hypertension is both a cause and consequence of chronic kidney disease (CKD). According to the Chinese national survey in 2007-2010, the prevalence of CKD was much higher in hypertensive patients (18.9%, n=16,691) than in the overall population sample (10.8%, n=47,204). CKD in hypertension confers risks to the kidneys as well as other organs. Probably because of high dietary salt intake, Asian hypertensive patients with CKD show high prevalence of non-dipping and reversed dipping blood pressure pattern, and may have even higher risks of cardiovascular disease. Therefore, out-of-office blood pressure evaluation and comprehensive cardiovascular evaluations are required. Most of current hypertension guidelines recommend intensive antihypertensive treatment in hypertensive patients with CKD. This is probably of particular relevance for cardiovascular prevention in Asia, because stroke, as a major complication of hypertension in Asia, is more closely related to blood pressure than coronary events. Intensive blood pressure control to 130/80 mmHg is often required to prevent CKD progression and cardiovascular complications. The inhibitors of the renin–angiotensin system (RAS) are recommended as the first line antihypertensive medications in patients with a glomerular filtration rate higher than 30 ml/min/1.73 m2, which may more efficaciously prevent end-stage renal disease and cardiovascular events. Nonetheless, combination therapy of RAS inhibitors with other classes of antihypertensive drugs, such as calcium-channel blockers, diuretics, etc, is required to control blood pressure to the target.

Original languageEnglish
Pages (from-to)181-185
Number of pages5
JournalCurrent Hypertension Reviews
Volume12
Issue number3
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Chronic Renal Insufficiency
Hypertension
Blood Pressure
Antihypertensive Agents
Calcium Channel Blockers
Glomerular Filtration Rate
Diuretics
Chronic Kidney Failure
Disease Progression
Cardiovascular Diseases
Salts
Stroke
Guidelines
Kidney
Therapeutics
Population

Keywords

  • Asia
  • Chronic kidney disease
  • Hypertension
  • RAS

ASJC Scopus subject areas

  • Internal Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG) (2016). Management of hypertension in patients with chronic kidney disease in Asia. Current Hypertension Reviews, 12(3), 181-185. https://doi.org/10.2174/1573402113666161122114854

Management of hypertension in patients with chronic kidney disease in Asia. / On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG).

In: Current Hypertension Reviews, Vol. 12, No. 3, 01.12.2016, p. 181-185.

Research output: Contribution to journalReview article

On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG) 2016, 'Management of hypertension in patients with chronic kidney disease in Asia', Current Hypertension Reviews, vol. 12, no. 3, pp. 181-185. https://doi.org/10.2174/1573402113666161122114854
On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG). Management of hypertension in patients with chronic kidney disease in Asia. Current Hypertension Reviews. 2016 Dec 1;12(3):181-185. https://doi.org/10.2174/1573402113666161122114854
On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG). / Management of hypertension in patients with chronic kidney disease in Asia. In: Current Hypertension Reviews. 2016 ; Vol. 12, No. 3. pp. 181-185.
@article{0973932a5a104dd3a980681ff5a8bbdf,
title = "Management of hypertension in patients with chronic kidney disease in Asia",
abstract = "Hypertension is both a cause and consequence of chronic kidney disease (CKD). According to the Chinese national survey in 2007-2010, the prevalence of CKD was much higher in hypertensive patients (18.9{\%}, n=16,691) than in the overall population sample (10.8{\%}, n=47,204). CKD in hypertension confers risks to the kidneys as well as other organs. Probably because of high dietary salt intake, Asian hypertensive patients with CKD show high prevalence of non-dipping and reversed dipping blood pressure pattern, and may have even higher risks of cardiovascular disease. Therefore, out-of-office blood pressure evaluation and comprehensive cardiovascular evaluations are required. Most of current hypertension guidelines recommend intensive antihypertensive treatment in hypertensive patients with CKD. This is probably of particular relevance for cardiovascular prevention in Asia, because stroke, as a major complication of hypertension in Asia, is more closely related to blood pressure than coronary events. Intensive blood pressure control to 130/80 mmHg is often required to prevent CKD progression and cardiovascular complications. The inhibitors of the renin–angiotensin system (RAS) are recommended as the first line antihypertensive medications in patients with a glomerular filtration rate higher than 30 ml/min/1.73 m2, which may more efficaciously prevent end-stage renal disease and cardiovascular events. Nonetheless, combination therapy of RAS inhibitors with other classes of antihypertensive drugs, such as calcium-channel blockers, diuretics, etc, is required to control blood pressure to the target.",
keywords = "Asia, Chronic kidney disease, Hypertension, RAS",
author = "{On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG)} and Huang, {Qi Fang} and Satoshi Hoshide and Cheng, {Hao Min} and Sungha Park and Park, {Chang Gyu} and Chen, {Chen Huan} and Kazuomi Kario and Wang, {Ji Guang}",
year = "2016",
month = "12",
day = "1",
doi = "10.2174/1573402113666161122114854",
language = "English",
volume = "12",
pages = "181--185",
journal = "Current Medical Imaging Reviews",
issn = "1573-4056",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Management of hypertension in patients with chronic kidney disease in Asia

AU - On behalf of the Characteristics On the Management of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG)

AU - Huang, Qi Fang

AU - Hoshide, Satoshi

AU - Cheng, Hao Min

AU - Park, Sungha

AU - Park, Chang Gyu

AU - Chen, Chen Huan

AU - Kario, Kazuomi

AU - Wang, Ji Guang

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Hypertension is both a cause and consequence of chronic kidney disease (CKD). According to the Chinese national survey in 2007-2010, the prevalence of CKD was much higher in hypertensive patients (18.9%, n=16,691) than in the overall population sample (10.8%, n=47,204). CKD in hypertension confers risks to the kidneys as well as other organs. Probably because of high dietary salt intake, Asian hypertensive patients with CKD show high prevalence of non-dipping and reversed dipping blood pressure pattern, and may have even higher risks of cardiovascular disease. Therefore, out-of-office blood pressure evaluation and comprehensive cardiovascular evaluations are required. Most of current hypertension guidelines recommend intensive antihypertensive treatment in hypertensive patients with CKD. This is probably of particular relevance for cardiovascular prevention in Asia, because stroke, as a major complication of hypertension in Asia, is more closely related to blood pressure than coronary events. Intensive blood pressure control to 130/80 mmHg is often required to prevent CKD progression and cardiovascular complications. The inhibitors of the renin–angiotensin system (RAS) are recommended as the first line antihypertensive medications in patients with a glomerular filtration rate higher than 30 ml/min/1.73 m2, which may more efficaciously prevent end-stage renal disease and cardiovascular events. Nonetheless, combination therapy of RAS inhibitors with other classes of antihypertensive drugs, such as calcium-channel blockers, diuretics, etc, is required to control blood pressure to the target.

AB - Hypertension is both a cause and consequence of chronic kidney disease (CKD). According to the Chinese national survey in 2007-2010, the prevalence of CKD was much higher in hypertensive patients (18.9%, n=16,691) than in the overall population sample (10.8%, n=47,204). CKD in hypertension confers risks to the kidneys as well as other organs. Probably because of high dietary salt intake, Asian hypertensive patients with CKD show high prevalence of non-dipping and reversed dipping blood pressure pattern, and may have even higher risks of cardiovascular disease. Therefore, out-of-office blood pressure evaluation and comprehensive cardiovascular evaluations are required. Most of current hypertension guidelines recommend intensive antihypertensive treatment in hypertensive patients with CKD. This is probably of particular relevance for cardiovascular prevention in Asia, because stroke, as a major complication of hypertension in Asia, is more closely related to blood pressure than coronary events. Intensive blood pressure control to 130/80 mmHg is often required to prevent CKD progression and cardiovascular complications. The inhibitors of the renin–angiotensin system (RAS) are recommended as the first line antihypertensive medications in patients with a glomerular filtration rate higher than 30 ml/min/1.73 m2, which may more efficaciously prevent end-stage renal disease and cardiovascular events. Nonetheless, combination therapy of RAS inhibitors with other classes of antihypertensive drugs, such as calcium-channel blockers, diuretics, etc, is required to control blood pressure to the target.

KW - Asia

KW - Chronic kidney disease

KW - Hypertension

KW - RAS

UR - http://www.scopus.com/inward/record.url?scp=85012079855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012079855&partnerID=8YFLogxK

U2 - 10.2174/1573402113666161122114854

DO - 10.2174/1573402113666161122114854

M3 - Review article

C2 - 27875953

AN - SCOPUS:85012079855

VL - 12

SP - 181

EP - 185

JO - Current Medical Imaging Reviews

JF - Current Medical Imaging Reviews

SN - 1573-4056

IS - 3

ER -